Can This Former Pandemic Star Make a Stunning Comeback?

Core Insights - Moderna's mRESVIA vaccine generated $2 million in sales and is approved for adults aged 60 and older in 40 countries, with additional approval for high-risk adults aged 18 to 59 in 31 countries [1] - Total revenue for the third quarter was reported at $1 billion, primarily driven by COVID vaccine sales of $971 million, including $781 million in the U.S. and $190 million internationally [2] - The company anticipates full-year U.S. revenue between $1 billion and $1.3 billion, reflecting ongoing volatility in vaccination trends [5] Financial Performance - Total product sales reached $973 million, with additional revenue of $43 million from collaborations and grants [2] - Moderna reported a net loss of $200 million due to decreased revenue, despite ending the quarter with $6.6 billion in cash and investments [5] - Analysts expect a GAAP loss of $2.60 per share for Q4, with revenue projected to fall by 37% to $623.9 million [8] Pipeline and Future Growth - Moderna has three approved products, with two programs reporting positive Phase 3 results and five additional candidates in clinical studies [6] - The company is developing a seasonal flu vaccine candidate, mRNA-1010, and a flu-plus-COVID combination vaccine, mRNA-1083, with regulatory filings expected before January 2026 [6] - Moderna is also expanding into oncology and rare diseases, with multiple late-stage studies underway in partnership with Merck [7] Market Position and Analyst Ratings - MRNA stock has risen 40% year-to-date but is down 25% from its 52-week high of $55.20 [3] - Analysts rate MRNA stock as a consensus "Hold," with two analysts rating it as a "Strong Buy" and one as a "Moderate Sell" [10] - The average target price for MRNA shares is $37.35, with a high price estimate suggesting potential upside of 228% over the next 12 months [10]